JS
Joseph Schwartz Leerink Partners Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
KalVista Pharmaceuticals
KALV
$765M
| $15.20 | $20 |
32%
upside
| Outperform | 1 month ago |
|
2
Insmed
INSM
$30.1B
| $142.53 | $115 |
19%
downside
| Outperform | 2 months ago |
|
3
Fulcrum Therapeutics
FULC
$372M
| $6.88 | $12 |
74%
upside
| Outperform | 3 months ago |
|
|
MAZE
4
Maze Therapeutics, Inc. Common Stock
MAZE
$660M
| $15.04 | $28 |
86%
upside
| Outperform | 6 months ago |
|
5
Travere Therapeutics
TVTX
$1.89B
| $21.15 | $40 |
89%
upside
| Outperform | 10 months ago |
|
6
Solid Biosciences
SLDB
$433M
| $5.56 | $12 |
116%
upside
| Outperform | 1 year ago |
|
|
MREO
7
Mereo BioPharma
MREO
$275M
| $1.73 | $8 |
362%
upside
| Outperform | 1 year ago |
|
8
Design Therapeutics
DSGN
$348M
| $6.11 | $6 |
2%
downside
| Market Perform | 2 years ago |
|
9
PTC Therapeutics
PTCT
$4.61B
| $58.01 | $48 |
17%
downside
| Market Perform | 2 years ago |
|
10
Pharvaris
PHVS
$1.41B
| $21.98 | $18 |
18%
downside
| Outperform | 2 years ago |
|
|
11
KalVista Pharmaceuticals
KALV
$765M
| $15.20 | $20 |
32%
upside
| Outperform | 2 years ago |
|
12
Ionis Pharmaceuticals
IONS
$9.46B
| $59.35 | $34 |
43%
downside
| Market Perform | 2 years ago |
|
13
BioMarin Pharmaceuticals
BMRN
$10.9B
| $56.75 | $130 |
129%
upside
| Outperform | 2 years ago |
|
14
Sarepta Therapeutics
SRPT
$1.93B
| $18.46 | $160 |
767%
upside
| Outperform | 2 years ago |
|
15
Ascendis Pharma
ASND
$12B
| $198.13 | $163 |
18%
downside
| Outperform | 2 years ago |
|
16
Gossamer Bio
GOSS
$571M
| $2.51 | $10 |
298%
upside
| Outperform | 2 years ago |
|
|
17
Solid Biosciences
SLDB
$433M
| $5.56 | $6 |
8%
upside
| Market Perform | 2 years ago |
|
|
MREO
18
Mereo BioPharma
MREO
$275M
| $1.73 | $4 |
131%
upside
| Outperform | 2 years ago |
|
19
Aurinia Pharmaceuticals
AUPH
$1.65B
| $12.53 | $12 |
4%
downside
| Outperform | 2 years ago |
|
20
Ultragenyx Pharmaceutical
RARE
$3.01B
| $31.28 | $108 |
245%
upside
| Outperform | 2 years ago |
|
|
21
Insmed
INSM
$30.1B
| $142.53 | $50 |
65%
downside
| Outperform | 2 years ago |
|
|
22
Travere Therapeutics
TVTX
$1.89B
| $21.15 | $38 |
80%
upside
| Outperform | 2 years ago |
|
23
Crinetics Pharmaceuticals
CRNX
$3.23B
| $34.25 | $39 |
14%
upside
| Outperform | 3 years ago |
|
24
Edgewise Therapeutics
EWTX
$1.54B
| $14.62 | $30 |
105%
upside
| Outperform | 3 years ago |
|
25
Avidity Biosciences
RNA
$6.24B
| $48.47 | $50 |
3%
upside
| Outperform | 3 years ago |
|